Sjödahl Jenny, Walter Susanna A, Johansson Elin, Ingemansson Anna, Ryn Ann-Katrine, Hallböök Olof
Department of Gastroenterology and Department of Clinical and Experimental Medicine, Linköping University , Linköping , Sweden.
Scand J Gastroenterol. 2015 Aug;50(8):965-74. doi: 10.3109/00365521.2014.999252. Epub 2015 Apr 20.
Biofeedback and medical treatments have been extensively used for moderate fecal incontinence (FI). There is limited data comparing and combining these two treatments. The objective of this study was to evaluate the effect of biofeedback and medical treatments, separately and in combination.
Sixty-four consecutive female patients, referred to a tertiary centre for FI, were included. The patients were randomized to start with either biofeedback (4-6 months) or medical treatment with loperamide and stool-bulking agents (2 months). Both groups continued with a combination of treatments, i.e. medical treatment was added to biofeedback and vice versa. A two-week prospective bowel symptom diary and anorectal physiology were evaluated at baseline, after single- and combination treatments.
Fifty-seven patients completed the study. Median number of leakage episodes during two weeks decreased from 6 to 3 (p < 0.0001) from baseline to completion. The patients showed a significant (1) decrease in number of leakages without forewarning (p = 0.04); (2) decrease in number of stools with urgency (p = 0.001); (3) decrease in number of loose stool consistency; and (4) an increase in rectal sensory thresholds, both for maximum tolerable rectal pressure and first sensation (<0.01). The combination treatment was superior to both single treatments in terms of symptoms and functions. There was no significant difference between the two groups at any time point.
The combination therapy with biofeedback and medical treatment is effective for symptom relief in FI. The symptom improvement was associated with improved fecal consistency, reduced urgency, and increased rectal sensory thresholds.
生物反馈疗法和药物治疗已广泛应用于中度大便失禁(FI)。比较和联合这两种治疗方法的数据有限。本研究的目的是评估生物反馈疗法和药物治疗单独及联合应用的效果。
纳入64例连续转诊至三级中心治疗FI的女性患者。患者被随机分为两组,一组先接受生物反馈治疗(4 - 6个月),另一组先接受洛哌丁胺和大便软化剂的药物治疗(2个月)。两组随后都继续接受联合治疗,即生物反馈治疗组添加药物治疗,药物治疗组添加生物反馈治疗。在基线、单一治疗和联合治疗后,对患者进行为期两周的前瞻性肠道症状日记记录及肛门直肠生理学评估。
57例患者完成了研究。从基线到研究结束,两周内漏便发作的中位数从6次降至3次(p < 0.0001)。患者在以下方面有显著改善:(1)无预警漏便次数减少(p = 0.04);(2)急迫性排便次数减少(p = 0.001);(3)稀便次数减少;(4)直肠感觉阈值增加,包括最大耐受直肠压力和首次感觉阈值(<0.01)。在症状和功能方面,联合治疗优于单一治疗。两组在任何时间点均无显著差异。
生物反馈疗法与药物治疗联合应用对缓解FI症状有效。症状改善与粪便性状改善、急迫感减轻和直肠感觉阈值增加有关。